Results 251 to 260 of about 44,321 (338)

A Phase 1 Dose‐Escalation, Food Effect, and Drug–Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR‐1505, in Healthy Volunteers

Clinical Pharmacology in Drug Development, Volume 15, Issue 1, January 2026.
Abstract SGR‐1505 is a novel small‐molecule inhibitor of MALT1, a key mediator of NF‐κB signaling implicated in the pathogenesis of B‐cell malignancies. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of SGR‐1505 in healthy volunteers. In this four‐part, open‐label study, 73 participants received single or multiple
Vipul K. Gupta, Brian Yoo, Daniel Weiss, Frank G. Basile, Edgar Schuck, Christopher M. Rubino, Sen Zhang, Stephen E. Maxwell, Wenxin Zheng, Joanne B. L. Tan, David Stenehjem, Paul B. Watkins, Margaret Dugan, Wu Yin, D. Hamish Wright, Karen Akinsanya, Jason Lickliter   +16 more
wiley   +1 more source

Erratum to "Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies" [Biomol Ther 32(6), 708-722 (2024)]. [PDF]

Biomol Ther (Seoul)
Choi SM, Lee JH, Ko S, Hong SS, Jin HE.
europepmc   +1 more source

Camelid immunoglobulins and nanobody technology [PDF]

, 2009
Baral, TN, De Baetselier, P, De Genst, E, Hassanzadeh-Ghassabeh, G, Kinne, J, Leonhardt, H, Magez, Stefan, Muyldermans, S, Nguyen, VK, Retarnozzo, VC, Revets, H, Rothbauer, U, Saerens, D, Stijemans, B, Tillib, S, Wernery, U, Wyns, L   +16 more
core   +1 more source

Foundational Principles for the Quantitative Translation of T‐Cell Therapeutics for Hematologic Malignancies and Immunology

Clinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 33-45, January 2026.
T‐cell engaging antibodies (TCEs) and chimeric antigen receptor (CAR) T cells (CAR‐T cells) are among precision medicine therapies that have revolutionized the treatment of hematologic cancers. Their success in oncology has piqued interest in translating this promise into additional indications, such as autoimmune disorders.
Peter Ashcroft, Sarah McFann, Alex Ferguson, Arthur Van De Vyver, Suzanne Gaudet, Eshita Khera, Jan‐Frederik Schlender   +6 more
wiley   +1 more source

Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US. [PDF]

Future Oncol
Mulvey E, Shafrin J, Than KS, Muthukrishnan S, Mutebi A, Chhibber A, Wang A, Alshreef A, Harb D, Gonzalez V, Quinlan S, Patel V, Johnson PC.   +12 more
europepmc   +1 more source

Targeting neutrophil‐driven immunosuppression: A strategy to overcome immune checkpoint inhibitor resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
TANs drive ICI resistance via antitumour immune remodelling, angiogenesis promotion, and elevation of tumour mutation burden Neutrophil biomarkers (e.g., NLR, TAN abundance) show strong predictive value for ICI response and prognosis. Targeting TAN recruitment, polarization, function and NETosis represents a promising strategy to overcome ICI ...
Ying Ning, Ke Lei, Xinyan Gao, Yan Kong, Yuping Shan, Tian Tian, Zhumei Cui, He Ren   +7 more
wiley   +1 more source

Bispecific Antibodies in Glioblastoma: Mechanistic Advances, Delivery Innovations, and Translational Challenges in Overcoming Immune Escape. [PDF]

Int J Med Sci
Wang HL, Chi N, Zhang HT.
europepmc   +1 more source

Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Application of synthetic lethality screening in drug resistance models. Abstract Background and Rationale Synthetic lethality (SL)‐based strategies hold significant promise for overcoming therapeutic resistance, a critical bottleneck in cancer treatment where cancer cells evade anticancer therapies, leading to diminished efficacy or treatment failure ...
Junyan Li, Liyuan Zhang, Yan Shang, Juan Liu, Hailong Zhao   +4 more
wiley   +1 more source

Mechanisms of Resistance to Novel Immunotherapies in B-Cell Lymphomas: Focus on CAR T and Bispecific Antibodies. [PDF]

Cancers (Basel)
Arena G, Chiarle R.
europepmc   +1 more source

Navigating the evolving management of smoldering multiple myeloma

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Smoldering multiple myeloma (SMM) represents an intermediate clinical stage between monoclonal gammopathy of undetermined significance (MGUS) and symptomatic multiple myeloma (MM). SMM carries a highly variable risk of progression to MM, requiring individualized risk stratification to guide management.
M. Bakri Hammami, Rafael R. Canevarolo, Ariosto S. Silva, Melissa Alsina, Nagi Kumar, Rachid Baz, Kenneth H. Shain   +6 more
wiley   +1 more source